What is Vizgen?
Vizgen is at the forefront of revolutionizing genomics with its innovative in situ single-cell spatial genomics tools. The company's MERSCOPETM Platform is setting a new standard by enabling researchers to visualize genome-scale nucleic acid imaging with exceptional accuracy and subcellular resolution. This capability is crucial for unlocking deeper insights into complex biological systems, impacting fields such as oncology, immunology, neuroscience, and drug discovery. Vizgen's technology empowers a spatial understanding of human health and disease, accelerating research and development across multiple life science disciplines.
How much funding has Vizgen raised?
Vizgen has raised a total of $139.7M across 4 funding rounds:
Series A
$14M
Series B
$37M
Series C
$85.2M
Debt
$3.5M
Series A (2020): $14M with participation from Northpond Ventures and ARCH Venture Partners
Series B (2021): $37M led by ARCH VENTURE PARTNERS, David Walt, Pura Vida Investments, and Tao Capital Management
Series C (2022): $85.2M supported by ARCH Venture Partners, Tao Capital Management, Blue Water Life Science Advisors, Sofina, Novalis LifeSciences, and Northpond Ventures
Debt (2025): $3.5M, investors not publicly disclosed
Key Investors in Vizgen
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Tao Capital Management
Tao Capital Management LLC is a company that operates in the Venture Capital & Private Equity industry, focusing on investments in life sciences and advanced technologies.
Sofina
Founded in 1980, Sofina is a private equity and venture capital firm specializing in direct and fund of funds investments, with a focus on growth capital and early to later-stage companies across various sectors including healthcare.
What's next for Vizgen?
The recent major strategic investment in Vizgen signals a strong validation of its technology and market potential. This influx of capital is expected to fuel further expansion of its MERSCOPETM Platform, enhance its research and development initiatives, and broaden its market reach. As Vizgen continues to scale, its focus will likely remain on solidifying its leadership in the spatial genomics sector, driving innovation in biological research, and accelerating the development of new therapeutics and diagnostics. The company's trajectory suggests a move towards broader commercialization and deeper integration into the research and clinical landscape.
See full Vizgen company page
